Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
16,785,250
-
Number of holders
-
17
-
Total 13F shares, excl. options
-
330,928
-
Shares change
-
+45,163
-
Total reported value, excl. options
-
$2,796,450
-
Value change
-
+$381,643
-
Number of buys
-
8
-
Number of sells
-
-3
-
Price
-
$8.45
Significant Holders of Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share (ELTX) as of Q3 2023
17 filings reported holding ELTX - Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share as of Q3 2023.
Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share (ELTX) has 17 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 330,928 shares
of 16,785,250 outstanding shares and own 1.97% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (140,527 shares), CM Management, LLC (65,000 shares), Nantahala Capital Management, LLC (30,000 shares), GEODE CAPITAL MANAGEMENT, LLC (27,874 shares), MILLENNIUM MANAGEMENT LLC (20,380 shares), CITADEL ADVISORS LLC (16,206 shares), MEYER HANDELMAN CO (13,899 shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (12,500 shares), BANK OF AMERICA CORP /DE/ (1,681 shares), and Steward Partners Investment Advisory, LLC (1,554 shares).
This table shows the top 17 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.